{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T20:48:54Z","timestamp":1649018934375},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10,1]]},"DOI":"10.1093\/ajhp\/56.19.1910","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T21:56:19Z","timestamp":1550872579000},"page":"1910-1910","source":"Crossref","is-referenced-by-count":0,"title":["Oral temozolomide approved for refractory brain tumor"],"prefix":"10.1093","volume":"56","author":[{"given":"Jane L.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/56\/19\/1910\/28474712\/ajhp1910.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T05:28:48Z","timestamp":1555478928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/56\/19\/1910\/5149764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,1]]},"references-count":0,"journal-issue":{"issue":"19","published-print":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/56.19.1910","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,10]]},"published":{"date-parts":[[1999,10,1]]}}}